We hold global, exclusive rights to two classes of monoclonal antibodies which inhibit bacterial enzymes critical for staph colonization of implanted devices. TPH 101 mimics the activity of an antibody found in some patients who successfully recover from septic joint revision surgery. The proposed indication is for prophylaxis in patients undergoing arthroplasty and other procedures where patients face high risk of staphylococcal infection.